NasdaqGM:KYMRBiotechs
Kymera Therapeutics (KYMR) Is Up 16.7% After KT-621 Trial Acceleration And Index Additions Has The Bull Case Changed?
In late June 2026, Kymera Therapeutics reported early completion of enrollment in its global BROADEN2 Phase 2b trial for KT-621 in moderate to severe atopic dermatitis, updated timing for topline data and potential Phase 3 initiation, announced Felix J. Baker as its new Board Chairman, and was added to multiple Russell value and small-cap indices.
The accelerated KT-621 trial timeline, combined with leadership changes and new index inclusions, highlights how Kymera is progressing its protein...